Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4680 |
Name | breast metaplastic carcinoma |
Definition | A breast carcinoma that represents a mixed group of malignant neoplasms characterized by the histologic presence of two or more cellular types. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast metaplastic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA H1047R | Buparlisib + Paclitaxel | breast metaplastic carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | breast metaplastic carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05810870 | Phase II | Eribulin + MEN1611 MEN1611 | PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA) | Recruiting | ESP | 0 |
NCT06026657 | Phase Ib/II | Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |